Stepan

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus across the top and bottom lines: revenue was $684.1M vs. $635.9M expected, and normalized EPS reached $1.18 vs. $0.61 expected. Adjusted EBITDA grew 45% YoY to $74.4M, driven by a 157% surge in Surfactant operating income despite a $5.1M restructuring headwind. Management's Project Catalyst efficiency plan is yielding early margin benefits, while Q2 volume growth of 3% (6% organic) suggests resilient demand in North American and Latin American markets.